The Freedom System includes the Freedom60® and FreedomEdge® Syringe Infusion Drivers, Precision Flow Rate Tubing™ and HigH-Flo Subcutaneous Safety Needle Sets™, and received its first FDA clearance in 1994. Through its Novel Therapies business, KORU Medical provides products for use by biopharmaceutical companies in feasibility/clinical trials during the drug development process.
Cyborg Score Rationale
The company achieved record revenue of $41.1 million in full year 2025, representing growth of 22% over the prior year and positive cash flow from operations for the full year. KORU Medical has been assigned a consensus recommendation of "Moderate Buy" from six research firms. However, the company remains micro-cap with limited scale.
Top Insights
Full year 2025 positive operating cash flow achieved with record revenue growth of 22% year-over-year
Recently received FDA 510(k) clearance for delivery of RYSTIGGO® (rozanolixizumab-noli), expanding label for FreedomEDGE® Infusion System
Market capitalization of $219.33 million with lean balance sheet (debt-to-equity ratio of 0.01)
Company rebranded from Repro Med Systems, Inc. to KORU Medical Systems, Inc. in March 2022
Named Competitors
Infusion Pumps and Systems — Large-scale infusion delivery systems for institutional settings
Home Infusion Services — Integrated home infusion therapy providers
Recent Developments
(January 2026) Hired Eric Schiller as Chief Technology Officer with equity incentive grants
(January 2026) Received FDA 510(k) clearance for RYSTIGGO® delivery capability
(January 2026) Reported preliminary 2025 results with record revenue of $41.1M and positive full-year operating cash flow
Open the full interactive KORU Medical Systems, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.